Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing closer to the ...

The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Lunit will use two of its AI-based SCOPE platform to analyze immunohistochemistry slides and the tumor microenvironment.

Anavex had proposed restricting the drug's indication to patients with early Alzheimer's without mutations in the SIGMAR1 gene.

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.